P53-based immunization is an attractive approach to
Introduction
The p53 tumor suppressor gene plays a central role in cell growth control and differentiation. Normally, p53 is a short-lived protein localized in nuclei of the cells. In response to DNA damage p53 becomes stabilized via phosphorylation of its N-terminus. 1 Stabilization of p53 can induce either a cell cycle arrest or programmed cell death (apoptosis). Cell cycle arrest is mediated by the ability of p53 to form homodimers that bind to specific DNA sequences and activate transcription of such cyclecontrol genes as p21, CIP1 (cdk-interacting protein 1), SDI1 (senescent cell-derived inhibitor 1), and 14-3-3 sigma. [2] [3] [4] These proteins inhibit cyclin-dependent kinases and induce a block at the G 1 /S or G 2 /M phases of the cell cycle. Induction of apoptosis is mediated via induction of apoptotic genes like BAX (Bcl-2 associated protein X) and a family of genes implicated in changes in the cellular redox state. 5, 6 About 50% of all human cancers have altered p53 function. In most cases it is due to stable missense mutations. 3 In contrast, alterations in other tumor suppressor genes are typically frameshift mutations and gross deletions and missense mutants are often unstable. The mutations Correspondence: DI Gabrilovich, in p53 gene result in accumulation of mutant p53 in nuclei and cytoplasm. The p53 can then be readily detected by immunohistochemistry or flow cytometry. In contrast to tumor cells, normal tissues have low to undetectable levels of p53 expression. 7 Inactivation of p53 function may also occur at the protein level due to complex formation with viral proteins, such as SV-40 T-antigen or adenovirus E1B-55K. In some cases, it may result in accumulation of wild-type p53. [8] [9] [10] Accumulation of p53 in tumor cells results in presentation of p53-derived antigens in the form of oligopeptides bound to MHC class I. These peptides may represent mutant, as well as wild-type portions of the protein. [11] [12] [13] [14] The difference in the expression of these antigens between normal and tumor cells laid a foundation for p53-based cancer immunotherapy. The high frequency of mutations in p53 gene in cancer makes this protein an attractive candidate for immunotherapy.
Over the last several years, different approaches to p53-based immunotherapy have been explored. Mutant p53 peptide-pulsed DCs were used in a number of studies. [13] [14] [15] [16] Although experiments in animals have demonstrated good anti-tumor results, this approach has serious limitations. It requires the identification of the site of mutation in each patient and matching of mutant peptides to patient's MHC class I motif. Furthermore, response against a single epitope may not necessarily be as effective as the poly-epitope response. Several groups investigated peptides derived from wild-type p53. Wild-type p53 peptide-specific cytotoxic T lymphocytes (CTLs) recognizing p53-overexpressing tumor cells in vitro were generated from human and murine lymphocytes. [17] [18] [19] [20] Those CTLs were also able to recognize an endogenously expressed murine and human wild-type p53 determinant and generate anti-tumor immune response in mice in vivo. 12, 21 This approach also has some limitations. The necessity for patient selection based on MHC class I motifs remains a prerequisite. In addition, defined peptide epitopes are not necessarily expressed on the surface of tumor cells, post-translational modifications may affect the recognition of tumor-associated peptides, and MHC class I-restricted peptides do not engage CD4
+ lymphocytes that play critical role in induction of a broad and effective immune response.
We have recently suggested an alternative approach based on the use of DCs modified to express the full open reading frame of the wild-type p53 gene. 22, 23 Although the potency of this approach has been demonstrated, several critical questions remained unanswered. The expression of wild-type p53 in normal tissues such as thymus may cause tolerance to this protein. 24, 25 Until now, only the human wild-type p53-containing-construct was used in both mouse and human models. Hence, whether DCs transduced with wild-type p53 gene are able to overcome such tolerance in vivo remains unclear. On the other hand, the generation of potent polyclonal CTL response against self-p53 may result in severe autoimmune abnormalities in normal tissues. Though, the adoptive transfer of wild-type p53-specific CTLs into tumor-bearing mice results in eradication of p53 overexpressing tumors without any damage of normal tissue, 12 it is still unknown if the induction of polyclonal immune response against p53 in vivo results in such damage. In order to clarify these questions we used DCs transduced with the murine wild-type p53 gene.
To address these question we, for the first time, used immunization with autologous mouse p53. We have shown that DCs transduced with wild-type p53 were not able to efficiently break tolerance to self-protein. Activation of DCs was a requirement for breaking tolerance to p53. Induced p53-specific immune response not only protected mice from tumor challenge, but also showed a prominent effect against established tumor without causing detectable autoimmune abnormalities.
Results
The efficiency of DC transduction with Ad-p53 was evaluated by intracellular staining with anti-p53 antibody ( Figure 1 ). Maximum transduction efficacy was found when 48-h infection with an MOI of 10 000 viral particles per cell was used (data not shown).
Activation of DCs by adenoviral construct and anti-CD40 antibody
The success of immunization among other factors depends on the function of administered DCs. Two methods have been used to assess DC function: the expression of surface molecules important for DC function (IA d , and B7-2) and allogeneic MLR (the function specifically attributed to DCs). DCs were generated from bone marrow cells as described above. Forty-eight hour infection with Ad-p53 resulted in a slight increase in the proportion of CD11c + B7-2 + activated DCs (from 23. 3.5% in control cells to 27.1 ± 2.5% in Ad-p53 infected cells, P > 0.1) (Figure 2a ). CD40 ligation induced the expression of B7-2 on the surface of DCs (from 23.9 ± 3.5% in control to 32.9% ± 2.7%, P Ͻ 0.05). The proportion of CD11c + B7-2 + became even higher when cells were both infected and treated with anti-CD40 antibody (35.7 ± 3.2%) (Figure 2a ). The ability of adenovirus to potentiate the activating effect of CD40 ligation was also observed in MLR. DCs infected with Ad-p53 stimulate allogeneic T cells to proliferate significantly more than untreated DCs. This effect was enhanced when a combination of Ad-p53 infection and CD40 ligation was used (Figure 2b ).
Protection against tumor formation and induction of CTL response in mice immunized with Ad-p53-transduced DCs
To induce an immune response against wild-type p53, we started with three immunizations of naive BALB/c mice with DCs generated from bone marrow progenitors of syngeneic mice and transduced with Ad-p53 as described in Materials and methods. Immunizations were performed at 10-14-day intervals. MethA sarcoma carrying the mutant endogenous p53 gene was chosen as a model for the evaluation of immune response against were inoculated s.c. into the shaved backs of immunized mice 7 days after the last immunization. We found no statistically significant differences in tumor formation between mice immunized with Ad-p53-transduced DCs and control (Ad-c-infected DCs) groups of mice (six mice per group). All mice in these groups developed MethA tumors by day 10 after the challenge with tumor cells (data not shown).
We hypothesized that three injections were not sufficient to overcome the tolerance to self-protein and tried to achieve better results by immunization of mice four times. The cumulative results of two experiments are demonstrated in Figure 3a . The difference between groups of mice treated with Ad-p53 and Ad-c DCs became statistically significant by day 19 after inoculation of tumor cells. However, the level of protection (60%) was far from optimal, and we tried to improve the results by activating DCs after infection. Dendritic cells infected with Ad-p53 or Ad-c for 24 h were collected and activated with CD40 ligation as described in Materials and methods. Mice were immunized with activated DCs and challenged with MethA sarcoma as described above. Nine out of 10 mice immunized with activated Ad-c DCs developed tumor by day 10 after inoculation of tumor cells. All mice immunized with activated Ad-p53-transduced DCs demonstrated tumor-protection by day 18 (Figure 3b) .
The presence of MethA sarcoma-specific CTLs was evaluated in mice immunized with activated Ad-p53-transduced DCs. Six-hour standard CTL assay was performed 1 month and a week after the last immunization (1 month after inoculation of MethA cells into immunized mice). Freshly isolated splenocytes were mixed with 51 Crlabeled MethA cells at different ratios. Splenocytes from mice injected with Ad-c-infected DCs demonstrated no ability to lyse target cells, whereas splenocytes from mice immunized with Ad-p53-transduced DCs demonstrated low, but clearly significant cytotoxicity against MethA sarcoma cells (Figure 3c ).
Treatment of tumor-bearing mice with Ad-p53-transduced DCs and CTL response in those mice
We investigated whether this approach might be used in cancer treatment. MethA sarcoma cells (5 × 10 5 ) were inoculated s.c. into the backs of BALB/c mice. The treatment was started 7 days later, when tumors reached 4-6 mm in diameter. DCs infected with Ad-p53 or Ad-c and activated by anti-CD40 antibody were injected i.v. (4 × 10 5 cells) and s.c. (2 × 10 5 cells) into tumor-bearing mice four times at 5-6-day intervals. No difference in tumor growth between non-treated (control) group of mice and group treated with Ad-c-infected DCs was found ( Figure  4a ). Tumor growth in mice treated with Ad-p53-transduced DCs was significantly slowed. Four out of six mice from this group rejected their tumors by day 17. Tumor growth in the remaining two mice resumed 1 week after the end of the treatment.
To evaluate the induced immune response, mice were killed 3 weeks after the last treatment. Splenocytes were restimulated with Ad-p53-transduced DCs for 7 days and used in 6-h standard CTL assay. Target cells were P815 cells infected with Ad-p53 or Ad-c. To measure the background level of killing, non-infected P815 cells were used. The p53 specific lysis reached 61% at effector/target 
Investigation of anti-adenoviral and autoimmune response in mice immunized with activated Ad-p53-transduced DCs
Titers of adenovirus-specific neutralizing antibody were evaluated in mouse sera collected 2, 3 and 4 weeks after the fourth immunization of mice with Ad-p53-transduced DCs or naive mice (three mice per group). The level of neutralizing antibody in mice treated with Adp53-transduced DCs ranged between 1/512 and 1/2048 dilutions with median 1/768. In naive mice, the titer did not exceed dilution 1/16.
To evaluate possible autoimmune abnormalities associated with p53-specific immunization, mice were injected with Ad-p53-transduced DCs four times at 10-12-day intervals. Four weeks after the last immunization mice were killed and tissues (pancreas, heart, liver, lymph node, colon, spleen, skin, lung, kidney, small bowel, thymus, and adrenal gland) were collected for histological analysis. Non-treated mice were used as control. No differences were found during gross examination of the autopsy material between the two groups. There was no evidence of inflammation, lymphocytic infiltrates, vasculitis or granulomata, and all organs showed normal histopathological features (data not shown).
Discussion
In this study we have demonstrated that activated DCs transduced with full-length wild-type p53 are able to break tolerance to this self-protein and induce potent antitumor response with no detectable autoimmune abnormalities.
Normal cells have very low or undetectable levels of p53, whereas accumulation of this protein due to mutations or functional inactivation is observed in approximately 50% of human malignancies. This makes p53 protein an attractive target for immunotherapy of cancer. We have recently suggested the use of DCs transduced with full-length wild-type p53 gene as a new strategy for p53-based immunotherapy of cancer. 22, 23 DCs were selected due to their unique ability to present antigens, express co-stimulatory molecules and promote immune response. The mode of antigen delivery is critical for the induction of an effective immune response to p53. 26 We chose an adenoviral vector to deliver the murine wild-type p53 gene into DCs because this method of gene delivery provides high efficiency and reliability (reviewed in Refs 27-29).
One of the major problems with adenoviral vectors is that they are highly immunogenic. Enhancement of the dose and frequent administration dramatically increase the titers of neutralizing antibody followed by reduction in the efficiency of gene delivery. 30 Adenovirus-mediated gene transfer into DCs, in contrast to direct administration of recombinant adenovirus, may not result in generation of significant anti-adenoviral response. Brossart et al 31 found only low titers of anti-adenovirus neutralizing antibody after repeated injections of adenovirus-infected DCs. The presence of those antibodies boosted the CTL response in mice and did not affect the anti-tumor activity of infected DCs. We have previously shown that repeated immunization of mice with adenovirus-infected DCs did not result in generation of adenovirus-specific CTL response. 22 These observations were further confirmed in the present study. Repeated immunization of mice with adenovirus-infected DCs produced the median titer of neutralizing antibody of less than 1:1000, whereas direct injections of the same virus (containing human instead of mouse p53 gene) into patients resulted in the titers ranging from 1:2000 to 1:200 000, with median titer of 1:20 000. The lower level of anti-adenoviral response after DC-based immunization may be explained by the fact that a significantly lower dose of adenovirus is used for DC transduction than for direct injection. It has been previously shown that dose of adenovirus closely directly correlated with the titer of neutralizing antibody. 30 In our study the level of neutralizing antibody was not sufficient to significantly affect the results of immunization.
Wild-type p53 is expressed by bone marrow-derived cells in the thymus. This causes negative selection of immature thymic T cells with high avidity for p53, which results in deletion of T cells able to recognize natural wild-type p53 epitopes presented by MHC class I molecules on tumor cells and thus prevents immune response. Only low avidity CTLs survive the induction of self-tolerance. 24 CD4 + T cells reactive to p53 exist in healthy individuals, and the epitopes are probably ignored by the immune system under normal physiological conditions. 32 Thus, the tolerance against wild-type p53
Gene Therapy is not complete and may be overcome under certain conditions. Generation of anti-tumor immunity by DCs correlates with DC maturation stage. 33 Taking into consideration that tumor dramatically affects DC maturation, function and survival, 34, 35 the induction of DC maturation in vitro may protect DCs from the negative influence of microenvironment in tumor tissue. This might also provide the most effective way of antigen presentation by DCs in vivo. A variety of signals such as microorganisms, cytokines, adhesion to extracellular matrix, and simple chemicals like haptens can induce activation of DCs.
36 CD40 is known to be critically involved in the differentiation, maturation and activation of DCs. CD40 ligand is expressed on activated T cells and stimulates DC secretion of IL-12, an important mediator of DC-supported differentiation of naive B cells and T cell activation. 37 Signaling via CD40 up-regulates the expression of costimulatory molecules, renders DCs more stimulatory for CD8
+ CTL directly and may be the key event that enables the DCs to stimulate T-killer cells. 37, 38 It was shown that bone marrow-derived DCs cultured in the presence of CD40 ligand exhibited the most potent immunostimulatory effects in comparison to other stimuli. 33 Klein and co-authors 39 demonstrated recently an improved survival of tumor-bearing mice treated with CD40L-transduced DCs. The absence of strong 'CD40 ligand-CD40' interactions may preserve tolerance to selfantigens. It can be responsible for the difficulty in eliciting CTL responses to weak antigens expressed by tumors. Collectively, these findings suggest that CD40 activation is the most promising approach to the breakage of tolerance in mice immunized against wild-type p53.
Immunization of mice with non-activated DCs transduced with mouse Ad-p53 prevented MethA sarcoma formation in 60% of mice. In our previous study, immunization of mice with non-activated DCs transduced with adenoviral construct containing human fulllength wild-type Ad-p53, resulted in complete tumor protection in 85% of mice challenged with human p53-carrying tumor cells and 72.7% of mice challenged with murine p53-expressing tumor cells. 22 Human and mouse p53 proteins have 81% homology, therefore there is a high chance that in mice, human p53 may represent a substantial number of foreign antigens. Immunization of mice with mouse wild-type p53 will have to counter the effect of tolerance to self-protein. A similar effect may be observed when patients will be treated with human wildtype-p53. Our data that activation of injected DCs by CD40 ligation help overcome this tolerance may have clear clinical implications.
We asked whether adenovirus itself can activate DCs. Adenoviral infection had slight activating effect on DCs. It manifested in an increased proportion of mature DC (CD11c + B7-2 + ) and increased ability to stimulate allogeneic T cells. It was consistent with a recent report that adenoviral infection induces partial maturation of human monocyte-derived DCs. 40 The report also demonstrated that triggering CD40 on adenovirus-transduced DCs produced more IL-12 and more efficient induction of Th1 responses than activation of DCs by CD40 ligand alone. 40 In our study, the combination of DC infection with CD40 ligation resulted in high expression of co-stimulatory and MHC class II surface molecules and enhanced the ability to stimulate the proliferation of T cells in allogeneic MLR. Taken together, this may explain why we achieved better results using DCs activated with CD40 ligation than DCs only infected with Ad-p53.
We found no signs of autoimmune disease in mice immunized with activated Ad-p53-transduced DCs. It is consistent with previously published data that CTLs specific to p53-derived peptides can somehow distinguish between tumor cells expressing self tumor-associated antigens and normal host cells in vitro. 13, 21 In vivo, adoptive transfer of p53-specific CTLs to nude mice with p53-overexpressing tumors caused eradication of tumor with no damage to normal tissue. 12 Our findings that activated DCs transduced with the wild-type p53 gene are able to overcome tolerance to selfp53 protein and induce a potent antitumor immune response without causing autoimmune abnormalities, suggest that this approach may be translated into clinical trials.
Materials and methods

Animals
Six-to 8-week-old female BALB/c and C57BL/6 mice were purchased from Harlan (Indianapolis, IN, USA) and housed in pathogen-free units in H Lee Moffitt Cancer Center, Tampa, FL, USA.
Cell lines
MethA cells were obtained from Dr LJ Old and cultured in complete culture medium (CCM) containing RPMI 1640 supplemented with 25 mM HEPES, 2 mM L-glutamine, 10% FCS, and antibiotics (100 units/ml penicillin, 100 g/ml streptomycin, 0.25 g/ml amphotericin B) (Life Technologies, Grand Island, NY, USA). MethA tumor is methylcholantrene-induced sarcoma developed in BALB/c mice and passaged as an ascitic tumor. It is a relatively immunogenic tumor that carries a mutant endogenous p53 gene. P815 mastocytoma cells were obtained from ATCC and cultured in CCM. The cell cultures were maintained at 37°C in a 5% CO 2 humidified atmosphere.
Reagents
Ad-mp53 was constructed by cloning the 1.5 kb murine p53 cDNA (obtained from Dr G Lozzano, MDACC) into pAd1/CMV that contains CMV promoter and bovine growth hormone polyA signal sequence. This plasmid was co-transfected with pBHG10 (Microbix, Ontario, Canada) into 293 cells. Recombinant adenovirus was selected based on PCR analysis of individual plaques. Control adenovirus (Ad-c) was prepared by deletion of E1 region from adenovirus serotype 5.
FITC-labeled mouse anti-mouse p53 antibody and isotype mouse IgG 2a were purchased from Serotec (Raleigh, NC, USA). FITC-labeled anti-mouse CD11c antibody and isotype mouse IgG 2a, , PE-labeled anti-mouse I-A d , antimouse CD86 (B7-2) antibody and isotype mouse IgG 2b, , as well as hamster anti-mouse CD40 (HM40-3) monoclonal antibody and anti-hamster IgM were purchased from PharMingen (San Diego, CA, USA).
Generation of dendritic cells
Dendritic cells were generated from bone marrow of naive syngeneic mice in CCM supplemented with 20 ng/ml murine GM-CSF, 10 ng/ml IL-4 (RDI, Flanders, NJ, USA), and 50 m 2-mercaptoethanol. The cells were maintained at 37°C in a 5% CO 2 -humidified atmosphere. Half of the medium was replaced on day 3. After 5-6 days in culture, cells were collected and enriched by centrifugation over a 13.5% metrizamide gradient (Accurate Chemical, Westbury, NY, USA). The purity of the DC fraction was higher than 80% as determined by FACS analysis of surface molecules expression (CD11c, CD11b, B7-2, I-A d ).
Infection of cells with adenovirus
Dendritic cells were infected with Ad-c or Ad-p53 (10 000 viral particles per cell) for 90 min in 0.5 ml serum-free RPMI 1640 medium supplemented with 20 ng/ml GM-CSF and 10 ng/ml IL-4 in 24-well plates followed by culturing in CCM with the same cytokines for 48 h. This dose was selected after some preliminary experiments, and did not affect cell viability (95% viable after trypan blue staining). P815 cells were infected as described above, but no cytokines were added to the culture medium.
Activation of DCs with mouse anti-CD40 antibody
Ligation of CD40 was performed as described elsewhere. 38 Briefly, DCs were washed twice in PBS and incubated with 14 g/ml hamster anti-mouse CD40 monoclonal antibody for 25 min on ice, then washed in RPMI 1640 twice and cultured in 1 ml CCM supplemented with 3.5 g/ml anti-hamster IgM, 20 ng/ml GM-CSF and 10 ng/ml IL-4 overnight.
FACS analysis of p53 and surface molecule expression
The efficacy of DC transduction with p53 was estimated by intracellular staining followed by flow cytometry. Cells were washed in PBS twice, fixed by 0.25% paraformaldehyde solution for 30 min on ice, washed in PBS, permeabilized by 0.2% Tween 20 for 15 min at 37°C, washed in PBS, incubated with FITC-labeled mouse antimouse p53 antibody or isotype mouse IgG 2a for 25 min on ice, washed twice in PBS and analyzed by FACScalibur (Becton Dickinson, Mountain View, CA, USA).
To study the expression of surface molecules, DCs were washed twice in PBS, incubated with 1 g/10 6 cells FITC-labeled anti-mouse CD11c antibody and PE-labeled anti-mouse I-A d or anti-mouse CD86 (B7-2) antibody for 25 min on ice, washed twice in PBS and analyzed by flow cytometry. Non-specific binding was estimated using FITC-labeled isotype mouse IgG 2a, and PE-labeled isotype mouse IgG 2b, .
Immunization and treatment of mice
For immunization, DCs were generated from bone marrow of BALB/c mice and infected with Ad-p53 or Adc as described above. Forty-eight hours later cells were washed three times in PBS and injected to BALB/c mice s.c. (2 × 10 5 DCs/mouse) and i.v. (4 × 10 5 DCs/mouse) three to four times with 10-14-day interval. In some experiments, DCs were activated with anti-CD40 antibody 24 h after infection and injected into mice the following day. Seven days after the last immunization MethA tumor cells (3.5 × 10 5 cells/mouse) were inoculated s.c., and mice were then observed for 3 weeks.
The same tumor model was used to evaluate the effect of treatment. Five hundred thousand MethA cells were inoculated s.c. into the shaved backs of BALB/c mice. The treatment was started when tumors reached 4-6 mm in diameter (day 7). Mice were treated with activated Adp53-or Ad-c-infected DCs prepared as described above. The treatment was repeated four times with 5-6-day intervals. Tumor sizes were measured every 3-5 days over 4 weeks.
CTL assay
Splenocytes (effector cells) freshly isolated or restimulated for 7 days with Ad-p53-or Ad-c-infected DCs were mixed with different 51 Cr-labeled target cells: MethA cells pre-incubated for 48 h with 5 ng/ml murine IFN-␥ or P815 cells infected with Ad-p53 or Ad-c. After 6-h incubation and harvesting of supernatants the radioactivity was measured by gamma-counter. To estimate the maximum 51 Cr-release 1% triton X-100 was used. The percentage of cell lysis was calculated as follows: ((experimental release -spontaneous release)/(maximum release -spontaneous release)) × 100%.
Allogeneic mixed leukocyte reaction (MLR)
Infected with Ad-p53 and/or activated DCs generated from bone marrow cells of BALB/c mice were co-cultured with T cells isolated from lymph nodes of C57BL/6 mice at ratios 1/50, 1/100, 1/200, 1/400 and 1/800 for 3 days followed by incubation with 1 Ci 3 H-thymidine (Amersham, Arlington Heights, IL, USA) for 16 h.
3 Hthymidine incorporation was measured in triplicates using a liquid scintillation ␤-counter.
Detection of anti-adenoviral response by neutralizing antibody assay
Mouse blood was collected by cardiac puncture. The sera were frozen and then used in neutralizing antibody assay. The titers of neutralizing antibodies were measured in indirect immunofluorescence assay by Virolab (Irving, CA, USA).
Preparation and staining of mouse tissues
During necropsy all mouse organs were grossly examined. Representative sections of each organ, less than 0.4 cm in thickness, were immediately placed in 10% neutral buffered formalin (formalin/tissue = 10/1), fixed for 24 h, and routinely processed to paraffin embedding. Sections, 5 microns in thickness, were stained with hematoxylin-eosin and examined under light microscopy. The morphological appearance of the tissues in immunized mice were compared with those in the naive animals.
Statistical analysis
Statistical analysis was performed using JMP statistical software (SAS Institute, Cary, NC, USA).
